In August 2018, the first of a new generation of intraocular lenses (IOLs), which will accommodate with the eye's muscle movements, has been implanted in a patient here at Auckland Eye as part of a multi-centre trial.
Power Vision's FluidVision's accommodating IOL is designed to "restore the vision of youth" by being adjustable to see near, far or anywhere in between for middle-aged or elderly patients affected by presbyopia or cataracts.
While other IOLs allow patients to regain clear vision, they cannot mimic the eye's natural accommodative process of dynamically adjusting focus at all distances, said PowerVision. The FluidVision IOL is designed to change its shape, similar to the natural lens. By becoming thicker when you need to see up close or thinner to see far away this gives patients freedom from ever needing glasses, contact lenses or any vision correction vision correction procedure again.
We are excited to announce that Auckland Eye is the lead and only New Zealand site for PowerVision's trial, which has been lead by Dr Dean Corbett, who was also the first surgeon in the world to implant a previous IOL-technological advancement, the Tecnis Symfony presbyopia-correcting lens in 2013. To read more on these 2013 trials, visit http://www.eyeonoptics.co.nz/articles/archive/fda-approved-iol-first-trialled-in-nz/
Though it is still early days for the patient, Dr Corbett said the procedure in August was an exciting day for all and so far, the outcome looks excellent. "It all went well, and the IOL looked magnificent in the eye. This is an entirely new concept in presbyopia correction. Potentially the only truly accommodating IOL designed to replicate the action of the young crystalline lens."
The FluidVision IOL contains a tiny amount of fluid inside the lens that moves in response to the natural muscle forces in the eye, providing "true accommodation" by mimicking the eye's natural accommodative process, changing the shape and becoming thicker when the patient needs to see up-close or thinner to see far away, said PowerVision.
When the eye moves to its natural accommodated state, the capsular bag squeezes a tiny amount of fluid (less than a drop) from the haptics at the periphery of the lens into the center. This inflates the lens, giving near vision. When the eye attempts to move to its disaccommodated state, the capsular bag squeezes fluid the other way. This deflates the lens, giving far vision.
The study is a prospective, randomised, bilateral, multicentre, subject and assessor-blinded, parallel- control design. Patients taking part in the trails will have a 50/50 chance to be randomly chosen to receive either the FluidVision AIOL or the PanOptix trifocal IOL. Neither the patient nor the person performing the vision tests after the surgery will know which lens the patient received. The study is being conducted across 15 study sites in Australia, New Zealand and South Africa.
Earlier clinical results have shown the FluidVision lens, which is implanted into the lens capsule like a standard IOL, provides excellent visual acuity and offers three to four dioptres of accommodative power, said PowerVision.
L. S. (2018, October). New IOL Trialled in NZ. New Zealand Optics, 6-6.